Researchers hope that women can use a single product to prevent HIV and unwanted pregnancies, and will start to achieve the goal when the vaginal ring containing the antiretroviral (ARV) drug dapivirin and hormonal contraceptives is first tested. An important step.
Women's one-month vaginal ring containing dapivirin has been found to be safe and helps prevent HIV in two large trials called "ASPIRE and drug rehabilitation centers." The dual-use ring currently tested in the Phase I trial of the Microbicide Testing Network (MTN) funded by the National Institutes of Health includes levonorgestrel (a synthetic progestin used in many contraceptives) and dapivirine. The number is large enough to prevent HIV and unwanted pregnancies for up to three months.
Dr. Sharon Hillier, Principal Investigator of MTN, said: “Many women who participated in the study told us that they wanted a single product that could provide contraception and prevent HIV. “We are very excited about the next generation of microbicide products, and we hope to solve them. This unmet need. Dr. Hillier is Professor and Vice President of the University of Pittsburgh School of Medicine, Director of Reproductive Infectious Diseases, and Director of the Department of Obstetrics and Gynecology and Reproductive Sciences.
The study, called MTN-030 / IPM 041, is working closely with the non-profit International Microbicide Initiative (IPM) in Pittsburgh and the Mam Women's Hospital (UMC) at the University of Birmingham in Alabama. IPM has developed a monthly dipavirin ring and a three-month dual-use ring, and a three-month Dapivirin ring that MTN will evaluate in another trial later this year.
The vaginal ring was first developed for contraceptive use. It is a flexible product that passes through the vagina and slowly releases the drug in the vagina over time.
Investigators will recruit 24 women to participate in MTN-030 / IPM 041. Half will receive a ring containing 200 mg of daclivirin alone, and the other half will receive a dual-use ring containing 200 mg of dapivirine and 320 mg of levonorgestrel. Participants will be required to wear the designated ring for 14 days, during which time investigators will closely monitor safety and measure how the body absorbs dapivirine and levonorgestrel in the presence of both drugs. The results are expected to come out in the middle of 2018.
JRT has been R&D Laser Distance Sensor every year. In this part, we put every new sensor here. To help our customer to find the lastest item. To know the updates we are doing, what's new for laser distance modules. What kind of Laser Distance Meter sensor we can make.
Best Regards
JRT Team
New Laser Distance Sensor,New Laser Distance Module,New Distance Sensor,New Laser Sensor
Chengdu JRT Meter Technology Co., Ltd , https://www.rangesensors.com